BGLC BioNexus Gene Lab Corp
- Stocks
- Basic Materials
- NASDAQ: BGLC
Price (delayed)
$5.39
Market cap
$9.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.53
Enterprise value
$9.08M
Relative Growth:
Rel. Growth:
10
Relative Strength:
Rel. Strength:
82
Relative Valuation:
Rel. Valuation:
26
Relative Profitability:
Rel. Profitability:
10
Highlights
The debt has dropped by 53% year-on-year
The EPS has plunged by 53% YoY and by 42% from the previous quarter
The quick ratio has declined by 41% year-on-year and by 15% since the previous quarter
Key stats
What are the main financial stats of BGLC
Market
Valuations
Earnings
Shares outstanding
1.8M
Market cap
$9.68M
Enterprise value
$9.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.29
Price to sales (P/S)
1.33
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.25
Revenue
$7.29M
Gross profit
$979,263
Operating income
-$4.79M
Net income
-$2.93M
EBIT
-$2.98M
EBITDA
-$2.81M
Free cash flow
-$3.32M
Per share
Balance sheet
Liquidity
EPS
-$1.53
EPS diluted
-$1.53
Free cash flow per share
-$1.85
Book value per share
$4.19
Revenue per share
$4.06
TBVPS
$5.24
Total assets
$9.42M
Total liabilities
$1.9M
Debt
$212,945
Equity
$7.52M
Working capital
$4.62M
Debt to equity
0.03
Current ratio
3.63
Quick ratio
2.88
Net debt/EBITDA
0.21
Margins
Efficiency
Dividend
EBITDA margin
-38.5%
Gross margin
13.4%
Net margin
-40.2%
Operating margin
-65.7%
Return on assets
-29.1%
Return on equity
-35.5%
Return on invested capital
-41.2%
Return on capital employed
-38.9%
Return on sales
-40.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BGLC stock price
How has the BioNexus Gene Lab stock price performed over time
Intraday
1.51%
1 week
5.27%
1 month
1.89%
1 year
48.48%
YTD
92.5%
QTD
-1.46%
Financial performance
How have BioNexus Gene Lab's revenue and profit performed over time
Revenue
$7.29M
Gross profit
$979,263
Operating income
-$4.79M
Net income
-$2.93M
Gross margin
13.4%
Net margin
-40.2%
The net margin has declined by 39% since the previous quarter and by 31% year-on-year
The operating income has declined by 38% year-on-year and by 10% since the previous quarter
The net income has contracted by 38% from the previous quarter and by 33% YoY
BioNexus Gene Lab's operating margin has decreased by 36% YoY and by 10% QoQ
Price vs fundamentals
How does BGLC's price correlate with its fundamentals
Growth
What is BioNexus Gene Lab's growth rate over time
Valuation
What is BioNexus Gene Lab stock price valuation
P/E
N/A
P/B
1.29
P/S
1.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.25
The EPS has plunged by 53% YoY and by 42% from the previous quarter
The P/B is 84% higher than the last 4 quarters average of 0.7
BioNexus Gene Lab's equity has decreased by 21% YoY and by 3.2% QoQ
BGLC's price to sales (P/S) is 90% more than its last 4 quarters average of 0.7
Efficiency
How efficient is BioNexus Gene Lab business performance
The return on equity has dropped by 54% year-on-year and by 47% since the previous quarter
The ROA fell by 49% YoY and by 45% QoQ
The return on invested capital has declined by 46% since the previous quarter and by 36% year-on-year
The ROS has contracted by 41% from the previous quarter and by 41% YoY
Dividends
What is BGLC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BGLC.
Financial health
How did BioNexus Gene Lab financials performed over time
The quick ratio has declined by 41% year-on-year and by 15% since the previous quarter
BioNexus Gene Lab's current ratio has decreased by 35% YoY and by 13% from the previous quarter
The debt is 97% smaller than the equity
The debt has dropped by 53% year-on-year
The company's debt to equity fell by 40% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.